Patents Issued in January 21, 2016
  • Publication number: 20160017300
    Abstract: Provided are a mismatch-specific cleavage reaction using a novel heat-resistant mismatch nuclease, a method for removing errors in a nucleic acid amplification reaction using the mismatch nuclease, a method for inhibiting the amplification of a nucleic acid having a specific base sequence during a nucleic acid amplification reaction, and a method for detecting a nucleic acid having a single-base polymorphic mutation using this inhibition method.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Applicant: TAKARA BIO INC.
    Inventors: Kiyoyuki MATSUMURA, Nariaki TAKATSU, Takashi UEMORI, Hiroyuki MUKAI
  • Publication number: 20160017301
    Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.
    Type: Application
    Filed: August 29, 2014
    Publication date: January 21, 2016
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Kamel Khalili, Wenhui Hu
  • Publication number: 20160017302
    Abstract: Embodiments of the present disclosure concern improvements to cell therapy for cancer. In certain embodiments, an ex vivo expanded T cell lacks endogenous heparanase expression, and amelioration of this effect allows an improvement for cancer cell therapy, including of solid tumors. In specific embodiments, ex vivo expanded T cells comprise recombinant heparanase expression.
    Type: Application
    Filed: March 5, 2014
    Publication date: January 21, 2016
    Inventors: Gianpietro Dotti, Dario Marchetti, Ignazio Caruana
  • Publication number: 20160017303
    Abstract: Disclosed are compositions and methods relating to variant alpha-amylases. The variant alpha-amylases are useful, for example, for starch liquefaction and saccharification, for cleaning starchy stains in laundry, dishwashing, and other applications, for textile processing (e.g., desizing), in animal feed for improving digestibility, and for baking and brewing.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicant: DANISCO US INC.
    Inventors: Luis G. Cascao-Pereira, Dina Finan, David E. Wildes, Marc Kolkman, Richard R. Bott, Pieter Augustinus, Roel Hermant, Monica Ocha Ruiz, Dewy Van Tol
  • Publication number: 20160017304
    Abstract: Disclosed are compositions and methods relating to variant alpha-amylases. The variant alpha-amylases are useful, for example, for starch liquefaction and saccharification, for cleaning starchy stains in laundry, dishwashing, and other applications, for textile processing (e.g., desizing), in animal feed for improving digestibility, and for baking and brewing.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicant: DANISCO US INC.
    Inventors: Luis G. Cascao-Pereira, Dina Finan, David E. Wildes, Marc Kolkman, Richard R. Bott, Pieter Augustinus, Roel Hermant, Monica Ocha, Dewy Van Tol
  • Publication number: 20160017305
    Abstract: Disclosed are compositions and methods relating to variant alpha-amylases. The variant alpha-amylases are useful, for example, for starch liquefaction and saccharification, for cleaning starchy stains in laundry, dishwashing, and other applications, for textile processing (e.g., desizing), in animal feed for improving digestibility, and for baking and brewing.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicant: DANISCO US INC.
    Inventors: Luis G. Cascao-Pereira, Dina Finan, David E. Wildes, Marc Kolkman, Richard R. Bott, Pieter Augustinus, Roel Hermant, Monica Ocha Ruiz, Dewy Van Tol
  • Publication number: 20160017306
    Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: October 5, 2015
    Publication date: January 21, 2016
    Inventors: Marc D. Morant, Paul Harris
  • Publication number: 20160017307
    Abstract: The present invention relates to novel polypeptides derived from endolysins from a bacteriophage of Clostridium perfringens and to nucleic acid molecules encoding the same, as well as compositions thereof. The invention also provides uses of such polypeptides and nucleic acid molecules in the diagnosis and treatment of conditions and diseases associated with microbial cells such as Clostridium perfringens. In particular, the invention provides a polypeptide having endolysin activity derived from bacteriophage ?CP51 of Clostridium perfringens and uses thereof.
    Type: Application
    Filed: August 5, 2015
    Publication date: January 21, 2016
    Inventors: Melina MAYER, Arjan NARBAD
  • Publication number: 20160017308
    Abstract: It discloses a use of N-acetylneuraminic acid aldolase with an amino acid sequence as shown in SEQ ID NO: 2 in catalytic synthesis of N-acetylneuraminic acid. The preparation of N-acetylneuraminic acid is to use the N-acetylneuraminic acid aldolase with the amino acid sequence as shown in SEQ ID NO: 2 as a catalyst, and N-acetylmannosamine and pyruvic acid as substrates.
    Type: Application
    Filed: November 27, 2013
    Publication date: January 21, 2016
    Applicant: Nanjing University of Technology
    Inventors: Jingjing Xie, Wenyan Ji, Hanjie Ying, Wujin Sun, Ting Guo, Yong Chen, Xiaochun Chen, Jinglan Wu
  • Publication number: 20160017309
    Abstract: Human cystathionine ?-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine ?-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine ?-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.
    Type: Application
    Filed: March 20, 2015
    Publication date: January 21, 2016
    Inventor: Jan P. KRAUS
  • Publication number: 20160017310
    Abstract: This disclosure relates to novel xylose isomerases and their uses, particularly in fermentation processes that employ xylose-containing media.
    Type: Application
    Filed: June 19, 2015
    Publication date: January 21, 2016
    Inventors: David Neal Nunn, JR., Peter Luginbuhl, Ling Li, Adam Martin Burja, Jon Peter Flash Bartnek
  • Publication number: 20160017311
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: February 12, 2015
    Publication date: January 21, 2016
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Publication number: 20160017312
    Abstract: The subject matter disclosed herein pertains to the modulation of a bacterial invasion switch and the subsequent use of the bacterium to vaccinate an organism. In one embodiment, the bacterial invasion switch is modulated by changing the proteolysis of ExoR protein. In another embodiment, a mutated bacterium produces a mutant ExoR protein that resists proteolysis.
    Type: Application
    Filed: September 14, 2015
    Publication date: January 21, 2016
    Inventors: Haiping Cheng, Shari Walcott, Haiyang Lu, Li Luo, Menghua Yang, Zahra Salehi
  • Publication number: 20160017313
    Abstract: Reversed phase-High Performance (High Pressure) Liquid Chromatography (RP-HPLC) and Size Exclusion Chromatography (SEC) methods have been developed for monitoring structural and size heterogeneity as well as stability of large RNA transcripts, including lengths of up to at least 10,000 nucleotides. The methods are designed for significantly larger mRNAs that could be monitored in the past, including lengths of up to at least 10,000 nucleotides, and including chemically modified RNA transcripts. SEC techniques are also used in the preparative purification of large RNA transcripts to remove impurities, including hybridized nucleic acid impurities and multimeric RNA species. All of these techniques are also beneficial in that they can be used for large scale manufacturing of therapeutics.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 21, 2016
    Inventors: Vlad Boris SPIVAK, Zahra SHAHROKH, William Joseph ISSA
  • Publication number: 20160017314
    Abstract: Methods are disclosed for isolating nucleic acids from formalin-fixed paraffin embedded (FFPE) tissue samples. Each of tissue samples contains paraffin and a target biological tissue or material, and the method includes the steps of: adding a first reagent and a second reagent to the FFPE tissue sample, the first reagent dissolving the paraffin material and the second reagent lysing the biological tissue; mixing the first reagent, the second reagent, and the FFPE tissue sample to form a first mixture; (2) heating the first mixture at 50-80° C. for 30-90 minutes; and then heating the first mixture at 80-95° C. for 30-90 minutes to fractionize the first mixture to form an aqueous phase and an oil phase; (3) collecting an aqueous solution from the aqueous phase; and (4) isolating nucleic acids from the aqueous solution. The method improves the efficiency and convenience of isolating nucleic acids from FFPE tissue samples.
    Type: Application
    Filed: September 30, 2015
    Publication date: January 21, 2016
    Inventors: Ting-Hao CHUNG, Cheng-Chun KUAN, Shih-Yu KUO
  • Publication number: 20160017315
    Abstract: The present invention relates to methods and kits which can be used to amplify nucleic acids with the advantage of decreasing user time and possible contamination. For easy processing and amplification of nucleic acid samples, the samples are bound to a solid support and used directly, without purification, in a nucleic acid amplification reaction such as the polymerase chain reaction (PCR).
    Type: Application
    Filed: March 14, 2014
    Publication date: January 21, 2016
    Inventors: Michael Kenneth Kenrick, Aidan Mark Emery, Fiona Elizabeth Allan, Bonnie Lee Webster, Erik Leeming Kvam, Wei Gao
  • Publication number: 20160017316
    Abstract: Disclosed herein are methods for isolation of long DNA molecules, for example megabase-sized genomic DNA molecules, from a biological sample, for example plant and animal tissues.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 21, 2016
    Inventor: Michael G. Saghbini
  • Publication number: 20160017317
    Abstract: The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.
    Type: Application
    Filed: February 26, 2014
    Publication date: January 21, 2016
    Inventors: George M. Church, Srivatsan Raman, Noah D. Taylor, Jameson Rogers
  • Publication number: 20160017318
    Abstract: Described herein are methods for determining the subgroup of medulloblastoma in a subject in need thereof. The subgroups of medulloblastoma include Group 3, Group 4, WNT and SHH. The subjects are children diagnosed with medulloblastoma or children suspected of having medulloblastoma.
    Type: Application
    Filed: July 21, 2015
    Publication date: January 21, 2016
    Applicant: Children's Hospital Los Angeles
    Inventors: Shahab Asgharzadeh, Ashley Margol, Richard Sposto
  • Publication number: 20160017319
    Abstract: A method of screening cell clones expressing a high yield of a polypeptide of interest is provided. The method employs the consecutive use of fluorescence activated cell sorting followed by colony picking based selection of cell clones with high expression rates and high proliferation rates. Furthermore, the invention pertains to a method of producing a polypeptide of interest using cells obtained by the described screening method.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 21, 2016
    Inventors: Audrey NOMMAY, Burkhard WILMS
  • Publication number: 20160017320
    Abstract: The present disclosure provides oligonucleotides that comprise semi-random barcode sequences. Such oligonucleotides may be incorporated into reverse transcription primers, PCR primers, or portions of sequencing adapters in preparing sequencing libraries. The resulting sequencing libraries can be used for accurate sequencing, including DNA or RNA counting and mutation detection. Methods and kits for preparing sequencing adapters and sequencing libraries are also provided.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 21, 2016
    Inventors: Yexun Wang, Zhong Wu
  • Publication number: 20160017321
    Abstract: The present invention relates to a microparticle comprising a functional microRNA/siRNA and application thereof. Specifically, disclosed is a use of a functional microRNA and/or siRNA, which is used to prepare a composition applied to a mammal. After the composition is applied, the microparticle is formed in a first part in an animal, and transported to a second part, which thereby improves physiological status of the second part or heals a disease of the second part. The second part is different from the first part. The use is beneficial for optimizing a dosing manner of the functional microRNA and/or siRNA.
    Type: Application
    Filed: June 21, 2013
    Publication date: January 21, 2016
    Inventors: Chenyu ZHANG, Ke ZENG
  • Publication number: 20160017322
    Abstract: Disclosed herein are methods, compositions, polynucleic acid polymers, assays, and kits for inducing processing of a partially processed mRNA transcript to remove a retained intron to produce a fully processed mRNA transcript that encodes a full-length functional form of a protein. Also described herein are methods and compositions for treating a disease or condition characterized by impaired production of a full-length functional form of a protein or for treating a disease or condition characterized by a defective splicing in a subject.
    Type: Application
    Filed: June 16, 2015
    Publication date: January 21, 2016
    Inventors: Igor Vorechovsky, Jana Kralovicova
  • Publication number: 20160017323
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: June 19, 2015
    Publication date: January 21, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Publication number: 20160017324
    Abstract: Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes at least one nucleotide comprising a chimeric organic composition. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide comprising a chimeric organic composition.
    Type: Application
    Filed: June 22, 2015
    Publication date: January 21, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brenda F. Baker, Anne B. Eldrup, Muthiah Manoharan, Balkrishen Bhat, Richard H. Griffey, Eric E. Swayze, Stanley T. Crooke
  • Publication number: 20160017325
    Abstract: Lipophilic oligonucleotide comprising a phosphate glycerol unit containing at least one aliphatic unsaturated carbon bond according to formula (I), with Oligonucleotide an unmodified or modified nucleic acid of 2-1000 nucleotides in length R=a bond or a linker unit Y?OH, SH or NHR3 X and Z=independently O, S or NR3 R3=hydrogen or branched or unbranched and/or substituted or unsubstituted alkyl, aryl and/or alkyl aryl residue with 10 to 30 carbon atoms R1, R2 branched or unbranched and/or substituted or unsubstituted alkyl, aryl and/or alkylaryl residue with 10 to 30 carbon atoms, with the provisio that at least one of the residues R1 or R2 comprises at least one aliphatic carbon-carbon double bond Use of lipophilic oligonucleotide according to Formula I for drug discovery or for transfection of cells.
    Type: Application
    Filed: March 18, 2014
    Publication date: January 21, 2016
    Applicant: MILTENYI BIOTEC GMBH
    Inventors: Dr. Eugen ULLMANN, Dr. Romualdus SMICIUS, Dr. Thomas ROCKEL
  • Publication number: 20160017326
    Abstract: Pharmaceutical compositions that include therapeutic agents including miRNA nucleic acid sequences are provided. Methods of diagnosing and treating a subjects suffering from a bone degenerative diseases including osteolytic bone metastasis are described.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 21, 2016
    Applicant: The Trustees of Princeton University
    Inventors: Yibin Kang, Brian Ell
  • Publication number: 20160017327
    Abstract: The present invention provides antisense phosphorodiamidate morpholino oligomers which are useful for the suppression or inhibition of the HTT gene involved in Huntington's disease. The oligomers can selectively suppress mutant forms of the HTT protein while allowing the normal protein to be expressed in sufficient quantity to retain its function in the cell. Methods for treatment of Huntington's disease are also provided.
    Type: Application
    Filed: July 6, 2015
    Publication date: January 21, 2016
    Inventors: Dobrila D. Rudnicki, Russell L. Margolis
  • Publication number: 20160017328
    Abstract: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of ?-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified motif or a positionally modified motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Application
    Filed: July 21, 2015
    Publication date: January 21, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Balkrishen Bhat, Thaza P. Prakash, Charles Allerson, Richard H. Griffey, Eric E. Swayze
  • Publication number: 20160017329
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: July 21, 2015
    Publication date: January 21, 2016
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Publication number: 20160017330
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: July 22, 2015
    Publication date: January 21, 2016
    Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Publication number: 20160017331
    Abstract: The present invention describes methods of treating cancer, cancer metastasis, and drug resistant cancers using miRNA inhibitors; for example, inhibitors of miR-409-5p, miR-409-3p, miR-154*. Also described are methods of using the miRNA as biomarkers; for example, to predict responsiveness to a cancer drug, to detect a disease state of cancer.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 21, 2016
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Leland W.K. Chung, Sajni Josson, Murali Gururajan, Anjali Jain
  • Publication number: 20160017332
    Abstract: The invention relates to an aptamer, the structure thereof comprising at least one nucleotide sequence 5?-GGCA(A/G)GGA-3?, that can specifically bind to the poly(A) hairpin of the 5?UTR region of the genome of the human immunodeficiency virus type 1 (HIV-1), providing the method for producing aptamers with said sequence by means of a combination of experimental techniques of in vitro selection of nucleic acids with computational techniques of sequence optimization. The invention also relates to a DNA gene structure for synthesizing said aptamers, preferably RNA. The invention further relates to the different uses of the above-mentioned aptamer, including the use thereof as a biosensor molecule for detecting and/or quantifying HIV-1, as an inhibitor of the production of viral particles of HIV-1, and to the application thereof in medicine, the invention also relating to a method for treating a disease caused by HIV-1, and to a pharmaceutical composition comprising said aptamer.
    Type: Application
    Filed: November 22, 2013
    Publication date: January 21, 2016
    Inventors: Alfredo BERZAL HERRANZ, Carlos BRIONES LLORENTE, Francisco José SÁNCHEZ-LUQUE, Susanna CUEVAS MANRUBIA, Michael STICH
  • Publication number: 20160017333
    Abstract: Materials and methods related to using multimeric DNA aptamers to treat demyelinating diseases are provided herein.
    Type: Application
    Filed: August 27, 2015
    Publication date: January 21, 2016
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Louis J. Maher, III, Moses Rodriguez
  • Publication number: 20160017334
    Abstract: Disclosed herein are synthetic oligoribonucleotides that form hairpin loop structures. The oligoribonucleotides can be used in the treatment of viral infection including prophylactic treatments. The oligoribonucleotides can also be used as adjuvants.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 21, 2016
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventor: John Hiscott
  • Publication number: 20160017335
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
    Type: Application
    Filed: December 5, 2013
    Publication date: January 21, 2016
    Inventors: Anna Borodovsky, Rajeev G. Kallanthottathil, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Muthiah Manoharan, Stuart Milstein
  • Publication number: 20160017336
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
    Type: Application
    Filed: May 28, 2015
    Publication date: January 21, 2016
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Akin Akinc
  • Publication number: 20160017337
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Application
    Filed: May 22, 2015
    Publication date: January 21, 2016
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • Publication number: 20160017338
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule or an equivalent thereof wherein a source of said miRNA molecule or equivalent thereof comprises at least 80 nucleotides and comprises a motif having at least 98% identity with the motif represented by SEQ ID NO:1 or a source thereof in a disease and condition associated with EMT (Epithelial to Mesenchymal Transition).
    Type: Application
    Filed: September 10, 2015
    Publication date: January 21, 2016
    Applicant: INTERNA TECHNOLOGIES B.V.
    Inventors: Roeland Quirinus Jozef SCHAAPVELD, Gerardus Wilhelmus Christiaan Theodoor VERHAEGH, Jacobus Antonius SCHALKEN, Andreas Alphons Franciscus Ludovicus van PUIJENBROEK, Willemijn Maria GOMMANS, Sanne WEIJZEN
  • Publication number: 20160017339
    Abstract: Provided are microorganisms that catalyze the synthesis of chemicals and biochemicals from a suitable carbon source. Also provided are methods of generating such organisms and methods of synthesizing chemicals and biochemicals using such organisms.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 21, 2016
    Inventors: James C. LIAO, Igor BOGORAD
  • Publication number: 20160017340
    Abstract: Methods, devices, and systems are provided for the delivery of agents (e.g., nucleic acids, proteins, organic molecules, organelles, antibodies or other ligands, 5 etc.) into live cells and/or the extraction of the same from said cells. In various embodiments the photothermal platforms and systems incorporating such photothermal platforms are provided that permit efficient, high-throughput cargo delivery into live cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Yi-Chien Wu, Ting-Hsiang S. Wu, Pei-Yu E. Chiou, Michael A. Teitell
  • Publication number: 20160017341
    Abstract: Provided is a ramp tag capable of solving instability in translation rate resulting from poor compatibility between codons in a foreign gene and a host when expressing a recombinant protein in E. coli. Unlike the conventional codon optimization or codon deoptimization method for solving the problem of rare codons, the present invention increases an expression efficiency of a target protein by merely having the ramp tag be fused with a target gene or independently expressed, without changing the original codon sequence, thereby allowing tRNA to be reused. Thus, the present invention provides a novel method for increasing recombinant protein expression which is capable of reducing costs and time in comparison to the codon optimization method that artificially synthesizes DNA sequences. Therefore, it is expected that the method of the present invention will be able to be used in production of high value-added pharmaceuticals or industrial enzymes.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 21, 2016
    Applicant: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun-Joong KIM, Won Ji PARK, Sung-Hwan YOU, Jin-Young LEE, Eun-Bin LEE, Sa-Young MIN
  • Publication number: 20160017342
    Abstract: The present invention provides compositions and methods comprising a low-phosphate repressible promoter. In particular, the present invention provides a low-phosphate repressible promoter from E. coli.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Inventors: Fernando Valle, Patricia Choudhary, Robert Osborne, Saul Nitsche Rocha, Monica Bhatia, U Loi Lao, Yihui Zhu
  • Publication number: 20160017343
    Abstract: The present invention relates to genetically modified host cells, in particular yeast cells, comprising at least one isolated polynucleotide encoding a Killer Expression protease (Kex2p) or a fragment and/or variant thereof which has at least one Kex2p functional activity and at least one isolated polynucleotide encoding a Protein Disulfide-Isomerase (Pdi1) or a fragment and/or variant thereof which has at least one Pdi functional activity.
    Type: Application
    Filed: March 6, 2014
    Publication date: January 21, 2016
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Yonghwan JIN, Yuan ZHU
  • Publication number: 20160017344
    Abstract: The present invention relates to the field of chromosome engineering. More specifically, the present invention provides methods and compositions useful for inducibly linearizing circular DNA molecules in vivo in yeast. In one embodiment, a comprises a nucleic acid encoding a selectable marker, wherein the nucleic acid encoding a selectable marker comprises an intron comprising an endonuclease recognition site flanked by telomere seed sequences.
    Type: Application
    Filed: March 6, 2014
    Publication date: January 21, 2016
    Inventors: Jef D. Boeke, Leslie Mitchell
  • Publication number: 20160017345
    Abstract: Methods of generating transgenic plants containing a gene of interest and a selectable marker encoding an enzyme that catalyzes oxidation of phosphite to phosphate.
    Type: Application
    Filed: September 30, 2015
    Publication date: January 21, 2016
    Inventors: Luis Rafael Herrera-Estrella, Damar L. López-Arredondo
  • Publication number: 20160017346
    Abstract: The invention relates to gene expression regulatory sequences from soybean, specifically to the promoter of a soybean predicted allergen Gly m Bd 28K peptide gene and fragments thereof and their use in promoting the expression of one or more heterologous nucleic acid fragments in a tissue-specific manner in plants. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the recombinant construct with the promoter, and methods for preparing and using the same.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 21, 2016
    Inventor: Zhongsen Li
  • Publication number: 20160017347
    Abstract: Described herein are the following: isolated polynucleotides, isolated polypeptides and recombinant DNA constructs; compositions (such as plants or seeds) comprising these recombinant DNA constructs; and methods of use for these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotide encodes a TMF polypeptide.
    Type: Application
    Filed: June 17, 2013
    Publication date: January 21, 2016
    Inventors: Stephen M. Allen, Zachary B. Lippman, Cora A. Macalister
  • Publication number: 20160017348
    Abstract: The present disclosure relates to recombinant proteins that induce epigenetic gene silencing and to methods of using such proteins for reducing the expression of genes in plants.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 21, 2016
    Applicant: The Regents of the University of California
    Inventors: Steve E. Jacobsen, Julie Law, Lianna Johnson
  • Publication number: 20160017349
    Abstract: Methods and compositions for maize target gene suppression and improving an agronomic trait through microRNAs or target gene modulation are disclosed. Polynucleotide constructs useful for gene silencing, or upregulation or modulation as well as cells, plants and seeds comprising the polynucleotides and methods for using microRNAs to silence a target gene are also described.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Inventors: Mule Ayele, KEVIN HAYES, CARL SIMMONS, SOBHANA SIVASANKAR, JOHN VAN HEMERT, BING-BING WANG